Literature DB >> 11471458

Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

X W Wang1.   

Abstract

Microinjection of expression vectors into cultured cells has been utilized to study functional interaction of p53 and the hepatitis B virus HBx gene in apoptosis. This approach allows us to determine protein-protein interactions in primary cultured human cells at a single cell level, including fibroblasts, mammary epithelial cells, renal epithelial cells, and hepatocytes. In principle, this approach can be used to study functional interaction of p53 and any gene that is either pro- or anti-apoptotic. The use of primary cultured human cells minimizes ambiguous results associated with immortalized or tumorigenic cell lines. Moreover, it is an easy and effective way to introduce genes of interests into primary human cells with defined genetic defects, thereby facilitating the delineation of genetic pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11471458     DOI: 10.1385/MB:18:2:169

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  79 in total

1.  trans-activation of viral enhancers by the hepatitis B virus X protein.

Authors:  D F Spandau; C H Lee
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Proteasome complex as a potential cellular target of hepatitis B virus X protein.

Authors:  J Huang; J Kwong; E C Sun; T J Liang
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice.

Authors:  O Terradillos; O Billet; C A Renard; R Levy; T Molina; P Briand; M A Buendia
Journal:  Oncogene       Date:  1997-01-30       Impact factor: 9.867

4.  X-gene product of hepatitis B virus induces apoptosis in liver cells.

Authors:  H Kim; H Lee; Y Yun
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

7.  Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma.

Authors:  F Henkler; N Waseem; M H Golding; M R Alison; R Koshy
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

8.  Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma.

Authors:  P Paterlini; K Poussin; M Kew; D Franco; C Brechot
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

9.  Hepatitis B virus X protein interacts with a probable cellular DNA repair protein.

Authors:  T H Lee; S J Elledge; J S Butel
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  3 in total

Review 1.  Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.

Authors:  Hoda Elkhenany; Ahmed Shekshek; Mohamed Abdel-Daim; Nagwa El-Badri
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line.

Authors:  Jian Guan; Xiao-Ping Chen; Hong Zhu; Shun-Feng Luo; Bin Cao; Lei Ding
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

3.  Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.

Authors:  Sufang Yang; Guohua Liu
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.